72P The risk factors of developing severity in immune checkpoint inhibitors-related pneumonitis in advanced lung cancer patients

Abstract

Immune checkpoint inhibitors (ICIs) have increasingly become an indispensable treatment strategy in advanced lung cancer, but may be associated with life-threaten immune checkpoint inhibitors-related pneumonitis (ICIP). Currently, there are no clear predictor factors for the development severity of ICIP. In this study, we evaluated the potential risk factors for the presence of severe ICIP in lung cancer patients treated with immunotherapy. This was a retrospective study. We included patients treated with immunotherapy between January 2017 to December 2021 in Shanghai Chest Hospital. The diagnosis and classification of ICIP according to the Common Terminology Criteria for Adverse Events (4.0). The clinical and treatment information in ICIP patients were collected and evaluated. A total of 524 lung cancer patients were included in the analysis, 55 (10.5%) were diagnosed with ICIP. The patients were divided into two groups based on clinical and radiological severity, of which 24 patients (43.6%) were divided into the severe groups and 31 patients (56.4%) were non-severe groups. No significant differences in clinical course, baseline characteristics, and peripheral-blood biomarkers between the two groups. However, the patients with prior radiotherapy history have an increased risk of severity (P<0.01). Among patients were diagnosed with ICIP, the history with prior radiotherapy is an independent predictor risk factor for developing severity in patients.